MLYS
Mineralys Therapeutics, Inc.
$29.85
-0.38
(-1.26%)
Mkt Cap
1.98B
Volume
760,565
52W Range
12.59-47.65
Sector
Healthcare
Beta
0.48
EPS (TTM)
-2.05
P/E Ratio
-15.88
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (154.65M) | (177.81M) | (71.90M) | (29.80M) | (19.41M) | (3.43M) |
| EPS | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Free Cash Flow | (142.43M) | (166.41M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| FCF / Share | -2.11 | -3.43 | -2.24 | -5.66 | -2.92 | -0.53 |
| Operating CF | (142.42M) | (166.31M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| Total Assets | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.50M |
| Cash & Equiv | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M | 1.41M |
| Book Value | 646.69M | 191.26M | 241.15M | (52.27M) | (22.93M) | (3.60M) |
| Return on Equity | -0.24 | -0.93 | -0.30 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (39.34M) | (32.23M) | (36.93M) | (43.27M) | (42.21M) | (48.95M) | (56.34M) | (41.01M) | (31.51M) | (24.39M) | (22.76M) | (12.14M) |
| EPS | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 | -0.61 | -0.57 | -0.31 |
| Free Cash Flow | (39.47M) | (37.90M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.22M) | (30.15M) | (19.20M) | (28.98M) | (19.03M) | (20.39M) |
| FCF / Share | -0.48 | -0.47 | -0.41 | -0.46 | -0.86 | -1.34 | -1.01 | -0.61 | -0.43 | -0.72 | -0.48 | -0.51 |
| Operating CF | (39.47M) | (37.89M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.19M) | (30.15M) | (19.14M) | (28.98M) | (19.03M) | (20.39M) |
| Total Assets | 652.86M | 661.81M | 599.95M | 335.72M | 354.94M | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M | 291.22M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M | 101.14M |
| Book Value | 638.14M | 646.69M | 576.43M | 313.55M | 341.56M | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M | 264.01M | 285.01M |
| Return on Equity | -0.06 | -0.05 | -0.06 | -0.14 | -0.12 | -0.26 | -0.24 | -0.14 | -0.10 | -0.10 | -0.09 | -0.04 |
MLYS News
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?